Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma. By admin / 12/05/2016
Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. By admin / 12/04/2016
Modulation of T cell Compartment in a Preclinical CLL Murine Model by a Selective PI3K delta inhibitor, TGR-1202. By admin / 12/04/2016
Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies By admin / 10/27/2016
Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses By admin / 09/14/2016
Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. By admin / 06/03/2016
Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL. By admin / 06/01/2016
Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. By admin / 06/01/2016
Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab By admin / 06/01/2016
Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor. By admin / 04/16/2016
